Document Detail

Myocardial protection with the non-selective endothelin receptor antagonist L-753,037 following acute coronary artery occlusion in the dog.
MedLine Citation:
PMID:  14716208     Owner:  NLM     Status:  MEDLINE    
Efficacy of a new, potent non-selective endothelin antagonist, l-753037, was examined in a model of canine coronary artery occlusion and reperfusion to assess whether blockade of both ETA and ETB receptors would enhance or reduce myocardial ischemic injury. Instrumented dogs were randomized to receive vehicle (n = 9) or l-753037 (0.1 microg/kg/min, n = 9) by intracoronary infusion 30 minutes before a 90-minute LCx coronary artery occlusion and through 4 hours of reperfusion. After 4 hours of reperfusion, plasma ET-1 levels rose significantly in both groups: 24 +/- 3 fmol/ml in vehicle animals (P < 0.01) versus 42 +/- 5 fmol/ml with l-753037 (P < 0.05). Treatment with l-753037 normalized total LCx flow and regional myocardial flow after 4 hours of reperfusion in all regions. LCx flow was reduced 16% from pre-occlusion baseline (P = 0.45) with treatment compared with 35% with vehicle (P < 0.01). Endocardial flow in the risk region returned to baseline values with l-753037 treatment but was reduced approximately 50% in vehicle animals. l-753037 treatment was associated with a 38% reduction in infarct size (24.1 +/- 3.9% AAR with l-753037 treatment versus 38.7 +/- 3.1% with vehicle, P < 0.01). Thus, a non-selective endothelin antagonist provides significant myocardial protection primarily by improving regional myocardial flow distribution following reperfusion and demonstrated no detrimental effects associated with blockade of the ETB receptor.
Stephen M Krause; Franklin C Clayton; David L Williams
Related Documents :
11509278 - Il-8 concentration in coronary sinus blood during early coronary reperfusion after isch...
2396328 - Myocardial ultrasonic backscatter for characterization of ischemia and reperfusion: rel...
19196828 - Rapid cooling preserves the ischaemic myocardium against mitochondrial damage and left ...
4140198 - The "no-reflow" phenomenon after temporary coronary occlusion in the dog.
15544078 - Does technical failure of revascularization during coronary artery bypass grafting pred...
11758978 - Interleukin-18 in patients with congestive heart failure: induction of atrial natriuret...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  43     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-01-12     Completed Date:  2004-08-17     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  214-21     Citation Subset:  IM    
Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / blood,  therapy
Myocardial Ischemia / prevention & control*
Myocardial Reperfusion Injury / prevention & control*
Pyridines / therapeutic use*
Receptors, Endothelin / antagonists & inhibitors*,  blood
Reg. No./Substance:
0/J 104132; 0/Pyridines; 0/Receptors, Endothelin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Disruption of the actin cytoskeleton up-regulates iNOS expression in vascular smooth muscle cells.
Next Document:  Endothelial and smooth muscle cell dysfunction in human atherosclerotic radial artery: implications ...